Zhejiang Wolwo Bio-Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Zhejiang Wolwo Bio-Pharmaceutical has been growing earnings at an average annual rate of 4.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 10.4% per year. Zhejiang Wolwo Bio-Pharmaceutical's return on equity is 12.7%, and it has net margins of 36%.
Key information
4.7%
Earnings growth rate
4.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 10.4% |
| Return on equity | 12.7% |
| Net Margin | 36.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Zhejiang Wolwo Bio-Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 881 | 317 | 401 | 118 |
| 31 Dec 23 | 848 | 310 | 384 | 112 |
| 30 Sep 23 | 870 | 292 | 380 | 108 |
| 30 Jun 23 | 893 | 316 | 378 | 107 |
| 31 Mar 23 | 882 | 328 | 365 | 104 |
| 01 Jan 23 | 896 | 349 | 361 | 106 |
| 30 Sep 22 | 888 | 391 | 357 | 103 |
| 30 Jun 22 | 849 | 372 | 339 | 100 |
| 31 Mar 22 | 841 | 359 | 341 | 95 |
| 31 Dec 21 | 808 | 338 | 336 | 88 |
| 30 Sep 21 | 765 | 324 | 320 | 78 |
| 30 Jun 21 | 724 | 319 | 303 | 75 |
| 31 Mar 21 | 691 | 308 | 283 | 70 |
| 31 Dec 20 | 636 | 278 | 263 | 61 |
| 30 Sep 20 | 630 | 281 | 257 | 56 |
| 30 Jun 20 | 624 | 275 | 257 | 48 |
| 31 Mar 20 | 612 | 274 | 257 | 42 |
| 31 Dec 19 | 639 | 298 | 259 | 37 |
| 30 Sep 19 | 615 | 290 | 256 | 29 |
| 30 Jun 19 | 556 | 259 | 235 | 19 |
| 31 Mar 19 | 532 | 247 | 222 | 16 |
| 31 Dec 18 | 501 | 233 | 205 | 12 |
| 30 Sep 18 | 478 | 227 | 188 | 10 |
| 30 Jun 18 | 439 | 211 | 171 | 11 |
| 31 Mar 18 | 411 | 200 | 163 | 9 |
| 31 Dec 17 | 386 | 186 | 158 | 6 |
| 30 Sep 17 | 367 | 175 | 156 | 5 |
| 30 Jun 17 | 344 | 154 | 157 | 0 |
| 31 Mar 17 | 324 | 139 | 153 | 0 |
| 31 Dec 16 | 312 | 129 | 151 | 0 |
| 30 Sep 16 | 303 | 129 | 141 | 0 |
| 30 Jun 16 | 283 | 121 | 136 | 0 |
| 31 Mar 16 | 277 | 122 | 130 | 0 |
| 31 Dec 15 | 267 | 118 | 126 | 0 |
| 30 Sep 15 | 261 | 116 | 121 | 0 |
| 30 Jun 15 | 252 | 112 | 118 | 0 |
| 31 Mar 15 | 247 | 110 | 116 | 0 |
| 31 Dec 14 | 240 | 100 | 122 | 0 |
| 30 Sep 14 | 228 | 90 | 121 | 0 |
| 30 Jun 14 | 211 | 78 | 116 | 0 |
| 31 Mar 14 | 202 | 68 | 114 | 0 |
| 31 Dec 13 | 194 | 71 | 102 | 0 |
Quality Earnings: 300357 has high quality earnings.
Growing Profit Margin: 300357's current net profit margins (36%) are lower than last year (37.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300357's earnings have grown by 4.7% per year over the past 5 years.
Accelerating Growth: 300357's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300357 had negative earnings growth (-3.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 300357's Return on Equity (12.7%) is considered low.